NFKB1 and acute lymphoblastic leukemia: - synergistic cytotoxic effects of bortezomib (20S proteasome inhibitor with Ki of 0.6 nM) and CX-4945 in acute lymphoblastic leukemia resulting in turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB